Arno Therapeutics and U.S. Army researchers to study antiviral effects of AR-12
Arno Therapeutics, a Flemington, New Jersey-based biopharmaceutical firm that focuses on the development of therapeutic agents to treat patients with cancer and other potentially fatal diseases, and the Army research institute will study the antiviral effects of AR-12, an orally-available small molecule agent, and a variety of related compounds on Ebola and other viruses.
"This is an important step forward in the process of evaluating AR-12 and the other compounds in the AR-12 series against various microbial pathogens," Arno Therapeutics CEO Alex Zukiwski said. "We look forward to working with (the Army institute) to learn more about the potential activity of AR-12 and related compounds."
More information can be found at www.arnothera.com.